CoChat

Predictors of Spontaneous and Systematically Assessed Suicidal Adverse Events in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) Study

Open access

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: The authors sought to identify predictors of self-harm adverse events in treatment-resistant, depressed adolescents during the first 12 weeks of treatment. METHOD: Depressed adolescents (N=334) who had not responded to a previous trial with an SSRI antidepressant were randomized to a switch to either another SSRI or venlafaxine, with or without cognitive behavior therapy. Self-harm events, i.e., suicidal and non-suicidal self-injury adverse events were assessed by spontaneous report for the first 181 participants, and by systematic weekly assessment for the last 153 participants. RESULTS: Higher rates of suicidal (20.8% vs. 8.8%) and nonsuicidal self-injury (17.6% vs. 2.2%), but not serious adverse events (8.4% vs. 7.3%) were detected with systematic monitoring. Median time to a suicidal event was 3 weeks, predicted by high baseline suicidal ideation, family conflict, and drug and alcohol use. Median time to nonsuicidal self-injury was 2 weeks, predicted by previous history of nonsuicidal self-injury. While there were no main effects of treatment, venlafaxine treatment was associated with a higher rate of self-harm adverse events in those with higher suicidal ideation. Adjunctive use of benzodiazepines, while in a small number of participants (N=10) was associated with higher rate of both suicidal and nonsuicidal self-injury adverse events. CONCLUSIONS: Since predictors of suicidal adverse events also predict poor response to treatment, and many of these events occurred early in treatment, improving the speed of response to depression, by targeting of family conflict, suicidal ideation, and drug use may help to reduce their incidence. The relationship of venlafaxine and of benzodiazepines to self-harm events requires further study and clinical caution.

Overview

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2008.08070976

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Research works printed but not linked: 9

  1. Apter A, 2006, J Child Adolesc Psychopharmacology, 16
  2. Hammad T, 2004, US Food and Drug Administration., 19
  3. Brent DA, JAMA 2008: 901-913
  4. US Food and Drug Administration, 2003, FDA Talk Paper.
  5. American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Health-IV
  6. Poznanski EO, 1984, Depression Rating Scale-Revised. Psychopharmacol Bull, 21, 979
  7. Guy W, 1976, Clinical Global Improvement Scale: Assessment Manual of Psychopharmacology 76
  8. Robin AL, 1995, Dictionary of Behavorial Techniques, 148
  9. Asarnow J, Keller MB

Cited by

See all 237

Metadata

Authors
Brent, D. A., Emslie, G. J., Clarke, G. N., Asarnow, J., Spirito, A., Ritz, L., Vitiello, B., Iyengar, S., Birmaher, B., Ryan, N. D., Zelazny, J., Onorato, M., Kennard, B., Mayes, T. L., DeBar, L. L., McCracken, J. T., Strober, M., Suddath, R., Leonard, H., Porta, G., & Keller, M. B.
Affiliations
University of Pittsburgh (US)
Venue
American Journal of Psychiatry
Published
2009-04
Volume
166
Issue
4
Pages
418-426
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2124714257
Cited by
235
References
34
Citations by year
2026: 5 · 2025: 6 · 2024: 4 · 2023: 17 · 2022: 7 · 2021: 14 · 2020: 19 · 2019: 12 · 2018: 10 · 2017: 10 · 2016: 13 · 2015: 10 · 2014: 14 · 2013: 17 · 2012: 25
FWCI
27.29
Type
journal article
Language
en
Open access
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
Funders
  • Bristol-Myers Squibb
  • Pfizer
  • National Institute of Mental Health (U01MH061835, U01MH062014)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
non-suicidal self-injury, treatment-resistant depression, adolescent depression, SSRI antidepressants, venlafaxine, cognitive behavioral therapy, suicidal ideation, family conflict, benzodiazepines, adverse event monitoring
MeSH terms
Venlafaxine Hydrochloride, Adolescent, Antidepressive Agents, Benzodiazepines, Cross-Sectional Studies, Cyclohexanols, Major Depressive Disorder, Depressive Disorder, Major, Drug Interactions, Drug Resistance, Drug Therapy, Combination, Female, Fluoxetine, Humans, Male, Suicide, Suicide, Attempted, Citalopram, Cognitive Behavioral Therapy, Self-Injurious Behavior, Selective Serotonin Reuptake Inhibitors, Paroxetine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Predictors of Spontaneous and Systematically Assessed Suicidal Adverse Events in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) Study. https://app.cochat.ai/papers/10.1176/appi.ajp.2008.08070976
The paper
Brent, D. A., Emslie, G. J., Clarke, G. N., Asarnow, J., Spirito, A., Ritz, L., Vitiello, B., Iyengar, S., Birmaher, B., Ryan, N. D., Zelazny, J., Onorato, M., Kennard, B., Mayes, T. L., DeBar, L. L., McCracken, J. T., Strober, M., Suddath, R., Leonard, H., . . . Keller, M. B. (2009). Predictors of Spontaneous and Systematically Assessed Suicidal Adverse Events in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) Study. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2008.08070976

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.